Get the Stockscreener App
0.888
0.91%
0.008
After Hours:
.90
0.012
+1.35%
Generation Bio Co stock is traded at $0.888, with a volume of 1.58M.
It is up +0.91% in the last 24 hours and down -23.45% over the past month.
Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
See More
Previous Close:
$0.88
Open:
$0.99
24h Volume:
1.58M
Relative Volume:
4.89
Market Cap:
$59.31M
Revenue:
-
Net Income/Loss:
$-126.61M
P/E Ratio:
-0.4531
EPS:
-1.96
Net Cash Flow:
$-60.14M
1W Performance:
-2.43%
1M Performance:
-23.45%
6M Performance:
-69.69%
1Y Performance:
-53.51%
1-Day Range:
$0.8756
$1.00
1-Week Range:
$0.8501
$1.0092
52-Week Range:
$0.75
$4.65
Generation Bio Co Stock (GBIO) Company Profile
Name
Generation Bio Co
Sector
Industry
Phone
857-529-5908
Address
301 BINNEY STREET, CAMBRIDGE
Compare GBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GBIO
Generation Bio Co
|
0.888 | 59.31M | 0 | -126.61M | -60.14M | -1.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.26 | 109.26B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
703.43 | 77.30B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.19 | 39.78B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.01 | 32.38B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.67 | 27.25B | 3.30B | -501.07M | 1.03B | -2.1146 |
Generation Bio Co Stock (GBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-19-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Nov-08-22 | Initiated | Canaccord Genuity | Buy |
| Dec-14-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-08-21 | Initiated | JMP Securities | Mkt Outperform |
| Feb-24-21 | Initiated | William Blair | Outperform |
| Feb-18-21 | Initiated | Needham | Buy |
| Jul-07-20 | Initiated | Cowen | Outperform |
| Jul-07-20 | Initiated | JP Morgan | Overweight |
| Jul-07-20 | Initiated | Jefferies | Buy |
| Jul-07-20 | Initiated | Wedbush | Outperform |
View All
Generation Bio Co Stock (GBIO) Latest News
Generation Bio Co. (NASDAQ:GBIO) Shares Sold by Jane Street Group LLC - Defense World
Layoff Tracker: Apellis, Barinthus, Repare Among Latest to Trim Workforces - BioSpace
Generation Bio director Quinn Anthony buys $203k in shares By Investing.com - Investing.com South Africa
Anthony G. Quinn Acquires 125,791 Shares of Generation Bio Co. (NASDAQ:GBIO) Stock - MarketBeat
Anthony G. Quinn Acquires 85,000 Shares of Generation Bio Co. (NASDAQ:GBIO) Stock - MarketBeat
Generation Bio director Quinn Anthony buys $203k in shares - Investing.com
Seattle immunotherapy startup Umoja Biopharma raises $100M - GeekWire
Generation Bio chief scientific officer Matthew Stanton to leave role - MSN
Generation Bio (GBIO) Stock Price, News & Analysis - MarketBeat
Needham & Company LLC Issues Pessimistic Forecast for Generation Bio (NASDAQ:GBIO) Stock Price - Defense World
Generation Bio's SWOT analysis: ctLNP tech drives pivot to autoimmune stock - Investing.com Canada
Verdiva Bio, a New Clinical-Stage Cardiometabolic Company, Launches with Over $410M in Series A Financing to Advance Next-Generation Therapies - Business Wire
Finance Watch: Generation Bio, CytomX Right-Size Operations Ahead Of J.P. Morgan - Citeline News & Insights
Needham & Company LLC Lowers Generation Bio (NASDAQ:GBIO) Price Target to $8.00 - MarketBeat
Barclays PLC Boosts Position in Generation Bio Co. (NASDAQ:GBIO) - Defense World
Generation Bio Announces Executive Departures and Appointments - Defense World
Generation Bio Restructures Leadership and Focuses on siRNA - TipRanks
Generation Bio Co. Announces Executive Changes - Marketscreener.com
Generation Bio Co. to Apply ctLNP Delivery Technology to Develop siRNA Therapeutics for T Cell-Driven Autoimmune Diseases - Marketscreener.com
Generation Bio to Apply ctLNP Delivery Technology to Develop siRNA Therapeutics for T Cell-Driven Autoimmune - EIN News
Generation Bio to Apply ctLNP Delivery Technology to Develop siRNA Therapeutics for T Cell-Driven Autoimmune Diseases - The Manila Times
Generation Bio Pivots to Autoimmune Disease Treatment with Novel T Cell Technology - StockTitan
Generation Bio Co. (NASDAQ:GBIO) Holdings Raised by State Street Corp - Defense World
Generation Bio Co. (NASDAQ:GBIO) Short Interest Up 16.3% in December - MarketBeat
Contrasting Spyre Therapeutics (NASDAQ:SYRE) & Generation Bio (NASDAQ:GBIO) - Defense World
Next-Generation Biomanufacturing Market Vendor and Technology Assessment Report 2024-2031 - openPR
Generation Bio stock hits 52-week low at $1.11 By Investing.com - Investing.com South Africa
MilliporeSigma to Acquire HUB Organoids Holding B.V., Advancing Next Generation Biology Portfolio - BioSpace
Generation Bio stock hits 52-week low at $1.11 - Investing.com
Generation Bio's SWOT analysis: innovative dna tech stock faces clinical hurdles By Investing.com - Investing.com South Africa
Generation Bio's SWOT analysis: innovative dna tech stock faces clinical hurdles - Investing.com Australia
BB Biotech AG Reduces Stake in Generation Bio Co: An In-Depth Analysis - GuruFocus.com
“Next-Generation Bioformulations” for Plant Growth Promotion and Stress Mitigation: A Promising Approach for Sustainable Agriculture | Request PDF - ResearchGate
Molecular Diagnostics Market to grow by USD 7.92 Billion (2024-2028), driven by rising age-related diseases; Report highlights AI-driven transformationTechnavio - Lelezard
US Penny Stocks Spotlight: LiveOne And 2 Other Promising Picks - Simply Wall St
Baker BROS. Advisors LP Acquires 737,988 Shares of Generation Bio Co. (NASDAQ:GBIO) - MarketBeat
Generation Bio Co. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Generation Bio Co. Reports Q3 2024 Financials and Progress - TipRanks
Generation Bio Co. (GBIO) Reports Q3 Loss, Tops Revenue Estimates - MSN
SK Bioscience's SKYCellflu Recognized as Next-generation World-class Product - BusinessKorea
Generation Bio's SWOT analysis: innovative gene therapy stock faces timeline hurdles - Investing.com Australia
Delve Bio and UCSF Publish Research Demonstrating Clinical Utility of Metagenomic Next-Generation Sequencing (mNGS) for Diagnosing Serious Neurological Infections - Business Wire
Next Generation Gene pioneers gene therapy approach with China data - BioWorld Online
FY2024 EPS Estimates for Generation Bio Boosted by Analyst - MarketBeat
Earnings Update: Generation Bio Co. (NASDAQ:GBIO) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts - Yahoo Finance
Landlord’s alleged breach doesn’t justify end of rent payments - Massachusetts Lawyers Weekly
Generation Bio Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance UK
Generation Bio Co Stock (GBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
9.31%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):